Skip to Content
Merck

Skip To

D7071

Dapoxetine hydrochloride

≥98% (HPLC)

Synonym(s):

(S)-N,N-dimethyl-1-phenyl-3-(1-naphthalenyloxy)propanamine hydrochloride, S-(+)-N,N-dimethyl-a-[2-(naphthalenyloxy)ethyl] benzenemethanamine hydrochloride, LY-210448 hydrochloride

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Pack SizeSKUAvailabilityPrice

About This Item

Empirical Formula (Hill Notation):
C21H23NO · HCl
CAS Number:
Molecular Weight:
341.87
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
Storage condition:
desiccated
Pricing and availability is not currently available.
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Quality Level

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +125 to +135°, c = 1 in methanol

storage condition

desiccated

color

white

solubility

DMSO: ≥20 mg/mL

originator

Eli Lilly

storage temp.

room temp

SMILES string

Cl.CN(C)[C@@H](CCOc1cccc2ccccc12)c3ccccc3

InChI

1S/C21H23NO.ClH/c1-22(2)20(18-10-4-3-5-11-18)15-16-23-21-14-8-12-17-9-6-7-13-19(17)21;/h3-14,20H,15-16H2,1-2H3;1H/t20-;/m0./s1

InChI key

IHWDIQRWYNMKFM-BDQAORGHSA-N

Gene Information

human ... SLC6A4(6532)

General description

Dapoxetine ((+)-(S)-N,N-dimethyl-(α)-[2(1naphthal enyloxy)ethyl]-benzenemethanamine hydrochloride) possess a similar structure as that of fluoxetine.

Biochem/physiol Actions

Potent Selective serotonin reuptake inhibitor (SSRI); used in treatment of premature ejaculation
Potent and selective SSRI
Dapoxetine is capable of blocking recombinant Kv4.3 potassium voltage-gated channels. It is considered as safe.

Features and Benefits

This compound is featured on the Biogenic Amine Transporters page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
SML0474M003PZ0365
assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

form

powder

form

powder

form

powder

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

100

storage temp.

room temp

storage temp.

room temp

storage temp.

-

storage temp.

room temp

storage condition

desiccated

storage condition

desiccated

storage condition

-

storage condition

desiccated

solubility

DMSO: ≥20 mg/mL

solubility

H2O: 5 mg/mL (clear solution, warmed)

solubility

H2O: >10 mg/mL

solubility

DMSO: 2 mg/mL, clear


pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 4 - Eye Irrit. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Nicola Mondaini et al.
Urology, 82(3), 620-624 (2013-08-31)
To assess both the acceptance and the discontinuation rates from dapoxetine, the first oral pharmacological agent indicated for the treatment of premature ejaculation (PE). One hundred twenty consecutive potent patients (mean age 40.3 years; range 18-63 years) seeking medical treatment
Shiwei Tang et al.
Advances in therapy, 36(8), 2096-2105 (2019-05-31)
Factors that impact the pharmacokinetics of dapoxetine, a 5-HT selective reuptake inhibitor used for the treatment of premature ejaculation, have not been clearly identified. This study aimed to evaluate the effects of consumption of a high-fat meal and cytochrome P450
Chris G McMahon et al.
The journal of sexual medicine, 8(2), 524-539 (2010-11-10)
Dapoxetine has been evaluated for the on-demand treatment of premature ejaculation (PE) in five phase 3 studies in various populations worldwide and has recently been approved in several countries. To present integrated efficacy and safety data from phase 3 trials



Questions

Reviews

No rating value

Active Filters